Nuvation Bio Inc.
NYQ: NUVBLive Quote
📈 ZcoreAI Score
Our AI model analyzes Nuvation Bio Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NUVB Z-Score →About Nuvation Bio Inc.
Healthcare
Biotechnology
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
📊 Fundamental Analysis
Nuvation Bio Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 633.1% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -53.2%, which indicates that capital utilization is currently under pressure.
At a current price of $4.60, NUVB currently sits at the 37th percentile of its 52-week range (Range: $1.57 - $9.75).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$1.60B
Trailing P/E
--
Forward P/E
-31.72
Beta (5Y)
1.61
52W High
$9.75
52W Low
$1.57
Avg Volume
4.89M
Day High
Day Low